Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03742895 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
A Phase 2 study of Advanced Solid Neoplasms, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 2
- Development phase
- 326
- Enrollment target
- 20
- Study locations
NCT03742895: Active Phase 2 study of Advanced Solid Neoplasms, sponsored by Merck Sharp & Dohme.
NCT03742895 is a Phase 2 study of Advanced Solid Neoplasms that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 326 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (145% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03742895, a Phase 2 study of Advanced Solid Neoplasms, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 326 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).
Primary Outcome
ORR was defined as the percentage of participants who have a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed by the BICR per modified RECIST 1.1. For participants with prostate cancer, response was assessed based on PCWG-modified RECIST 1.1 criteria (CR: soft tissue CR with no evidence of disease \[NED\] on bone scan; PR: soft tissue PR with non-progressive disease, non-e
Conditions Studied
Interventions
- DRUG Olaparib
Study Locations (20)
New York
- Memorial Sloan-Kettering Cancer Center at West Harrison ( Site 0126) - Harrison
- VA New York Harbor Healthcare System Manhattan ( Site 0094) - New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0057) - New York
- Memorial Sloan Kettering Cancer Center ( Site 0026) - New York
California
- St Joseph Heritage Healthcare-Oncology ( Site 0056) - Fullerton
- Cedars Sinai Medical Center ( Site 0002) - Los Angeles
- UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0007) - San Francisco
Georgia
- Winship Cancer Institute of Emory University ( Site 0025) - Atlanta
- Augusta University ( Site 0028) - Augusta
Maryland
- University of Maryland ( Site 0050) - Baltimore
- Weinberg Cancer Institute at Franklin Square ( Site 0054) - Baltimore
Arizona
- The University of Arizona Cancer Center - North Campus ( Site 0011) - Tucson
Colorado
- Rocky Mountain Regional Veterans Affairs Medical Center ( Site 0092) - Aurora
Kentucky
- Markey Cancer Center ( Site 0018) - Lexington
Massachusetts
- University of Massachusetts ( Site 0017) - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2018-12-12 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
What the registry record for NCT03742895 still lists
NCT03742895 is an interventional study that assigns participants to a tested intervention. The registered 326 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (145% higher).
The record links to 1 condition, with Advanced Solid Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Olaparib is the first listed.
NCT03742895 names 20 study sites across 13 states, led by New York, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT03742895 about?
NCT03742895 is a clinical study titled "Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)". This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair ...
What is the current status of trial NCT03742895?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 326 participants. The study started on 2018-12-12. Estimated completion is 2026-06-30.
What conditions does trial NCT03742895 study?
This clinical trial studies the following conditions: Advanced Solid Neoplasms.
What interventions are being tested in trial NCT03742895?
The interventions under investigation include: Olaparib (DRUG).
Who is sponsoring clinical trial NCT03742895?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03742895 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03742895's enrollment target sits among peer trials
326 147th of 2000 higher than 1,853 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06410144 · 326 participants · NA
Chronic Kidney Disease-Education (CKD-EDU)
- NCT06586619 · 326 participants · NA
A Remotely Delivered Tai Chi/Qigong Intervention for Older People Living With HIV
- NCT07040566 · 326 participants · Phase 2
A Trial of Varenicline for E-cigarette Cessation
- NCT07165860 · 326 participants · NA
Clinical Trial to Reduce Perinatal Intimate Partner Violence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI